A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Conditions

• Neoplasms
• Solid Tumors

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• GSK5733584 — DRUG
  GSK5733584 will be administered

Study Details

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Key Dates

Start date

Jul 2, 2024

Status verified

May 2026

Primary completion

Sep 22, 2027

Completion

Dec 31, 2029

Study Design

Enrollment

675 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Part 1: Dose Escalation
  Participants with advanced solid tumors who are refractory or intolerant to established standard therapies
• Experimental: Part 2: Dose Expansion
  Participants with platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC)

Primary Outcome Measure

Part 1: Number of participants with dose limiting toxicity (DLT) [ Time Frame: Up to 21 days ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (18)

Find similar trials in Birmingham, AL

Related Studies

• Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
  Recruiting · Stanford University · Stanford, California
• Collection of Tissue Samples for Cancer Research
  Recruiting · National Cancer Institute (NCI) · Sacramento, California
• A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
  PHASE1/PHASE2 · Enrolling By Invitation · Dipnarine Maharaj · Boynton Beach, Florida
• CIBMTR Research Database
  Recruiting · Center for International Blood and Marrow Transplant Research · Minneapolis, Minnesota